Merck and Parexel said that under the contract, a Merck BioVentures unit will be established within the Parexel organization.
Parexel chairman and CEO Josef von Rickenbach said they are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this rapidly developing market segment for the benefit of patients worldwide.
Merck BioVentures president Michael Kamarck said through this agreement, Merck BioVentures has secured strategic access to Parexel’s proven biosimilar clinical development experience.